Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

EClinicalMedicine·2026
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

JCO precision oncology·2026
Same author

Zika virus recruits karyopherin α6 for efficient replication via NS2B.

Journal of virology·2026
Same author

MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models.

Cancer research communications·2026
Same author

Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target.

Pharmacological reports : PR·2026
Same journal

Whole-Embryo 3D Quantification Reveals Conserved Topological Design and Scaling of Germ Layers in Xenopus.

bioRxiv : the preprint server for biology·2026
Same journal

scRNA-seq and genomics analyses reveal key mechanisms of inverted papilloma-associated sinonasal squamous cell carcinoma malignant transformation.

bioRxiv : the preprint server for biology·2026
Same journal

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

bioRxiv : the preprint server for biology·2026
Same journal

A human-specific genetic modifier reconfigures large-scale cortical network dynamics underlying behavioral performance.

bioRxiv : the preprint server for biology·2026
Same journal

<i>Staphylococcus aureus</i> uses a eukaryotic-like uridyltransferase to make UDP-GlcNAc for cell wall synthesis.

bioRxiv : the preprint server for biology·2026
Same journal

Dynamic redistribution of eIF4F controls cap-dependent translation initiation.

bioRxiv : the preprint server for biology·2026
查看所有相关文章

相关实验视频

Updated: Jan 18, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

903

工程功能 优化全人B7-H3 CAR T细胞,用于增强固体瘤治疗.

Pradip Bajgain, Yang Feng, Mariela Puebla

    bioRxiv : the preprint server for biology
    |January 16, 2026
    PubMed
    概括
    此摘要是机器生成的。

    完全人类的B7-H3特异性抗体被开发用于嵌合抗原受体 (CAR) T细胞疗法. 与现有疗法相比,这些新型CAR T细胞在实体瘤模型中表现出更高的疗效和安全性.

    更多相关视频

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    1.4K
    Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
    06:22

    Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

    Published on: February 2, 2024

    4.8K

    相关实验视频

    Last Updated: Jan 18, 2026

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
    06:10

    Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

    Published on: May 9, 2025

    903
    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    1.4K
    Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
    06:22

    Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

    Published on: February 2, 2024

    4.8K

    科学领域:

    • 免疫学 免疫学 免疫学
    • 在瘤学瘤学.
    • 生物技术是生物技术.

    背景情况:

    • B7-H3是一种与瘤相关的抗原,在各种固体瘤中过度表达.
    • 目前的B7-H3仿真抗原受体 (CAR) T细胞疗法利用来自小鼠的抗体,冒着免疫排斥的风险.
    • 现有的CAR T细胞疗法因非人类抗体序列的免疫性而面临挑战.

    研究的目的:

    • 为了生成完全人类B7-H3特定的单链可变片段 (scFvs),以改善CAR T细胞治疗.
    • 在临床前固体瘤模型中评估新型人类B7-H3CAR T细胞的疗效和安全性.

    主要方法:

    • 实验室菌体显示技术用于隔离完全人类B7-H3特异性scFvs.
    • 用人类领先的粘合剂Y111进行工程的CAR T细胞在胰腺癌,神经母细胞瘤和质母细胞瘤异种移植模型中进行了测试.
    • 对基于Y111的CAR T细胞与来自小鼠的CAR T细胞进行比较分析 (376.96和MGA271).

    主要成果:

    • 结合Y111结合剂的CAR T细胞在异种移植模型中耐受性良好.
    • 与基于376.96和MGA271的CAR相比,基于Y111的CAR T细胞表现出更高的抗瘤活性.
    • Y111 CAR治疗导致了完整的反应,瘤排斥和显著的生存益处.

    结论:

    • 全人类B7-H3结合剂Y111是开发下一代CAR T细胞疗法的有希望的候选者.
    • 基于Y111的CAR T细胞为固体瘤提供了潜在的更安全,更有效的治疗策略.
    • 这项研究强调了全人类结合剂在CAR T细胞治疗中克服免疫性问题的优势.